New therapies for glioblastoma (GBM) are needed, as five-year survival is <10%. The proteasome inhibitor marizomib (MRZ) has inhibitory and death-inducing properties unique from previous inhibitors such as bortezomib (BTZ), and has not been well examined in GBM. We evaluated the mechanism of death and in vivo properties of MRZ in GBM. The activation kinetics of initiator caspases 2, 8, and 9 were assessed using chemical and knockdown strategies to determine their contribution to cell death. Blood brain barrier permeance and proteasome inhibition by MRZ and BTZ were examined in an orthotopic GBM model. Blockade of caspase 9, relative to other caspases, was most protective against both MRZ and BTZ. Only MRZ increased the proteasome substrate p27 in orthotopic brain tumors after a single injection, while both MRZ and BTZ increased p21 levels after multiple treatments. Cleavage of caspase substrate lamin A was increased in orthotopic brain tumors from mice treated with MRZ or BTZ and the histone deacetylase inhibitor vorinostat. Our data indicate that MRZ induces caspase 9-dependent death in GBM, suggesting drug efficacy biomarkers and possible resistance mechanisms. MRZ reaches orthotopic brain tumors where it inhibits proteasome function and increases death in combination with vorinostat.
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with a median survival of 14 months 1,2 . New therapeutic strategies are needed for GBM, and one approach involves targeting the proteasome, the complex responsible for the bulk of protein degradation in cells. Proteasome inhibition leads to toxic accumulation of misfolded and abnormal proteins in cells and can also stabilize specific tumor inhibitory factors such as cell cycle regulatory proteins and pro-apoptotic factors [3] [4] [5] . Proteasome inhibitors have been shown to activate cell death in different types of cancer, including multiple myeloma and leukemia, in a manner dependent on activation of caspases and apoptotic cell death [6] [7] [8] . The proteasome inhibitor bortezomib (BTZ) is FDA-approved for multiple myeloma and mantle cell lymphoma 9 and has been evaluated clinically in GBM. Other proteasome inhibitors have also been developed, including marizomib (MRZ, formerly NPI-0052) 10, 11 . As an irreversible inhibitor, MRZ is unique from BTZ, which is a slowly reversible inhibitor [12] [13] [14] . While both MRZ and BTZ target the chymotryptic-like activity of the β5 proteasome subunit, they target the other catalytic activities to different extents, with MRZ inhibiting the trypsin-like activity of the β 2 subunit more strongly than BTZ 15 . Also, MRZ is more dependent on caspase 8 than BTZ in myeloma and leukemia 8, 16 and MRZ induces death in BTZ-resistant myeloma cells 15 , demonstrating that these inhibitors can trigger different death pathways. A phase I study of MRZ in relapsed multiple myeloma is currently ongoing, and there are plans to initiate a phase I trial in GBM 17 .
In vitro studies have mainly utilized MTT assays to demonstrate that MRZ and BTZ cause death in GBM cell lines 18, 19 . Also, BTZ induces cleavage of poly(ADP ribose) polymerase 20 , suggesting a caspase-dependent mechanism of death. However, the mechanism of death induced by MRZ, and its dependence on specific initiator caspases, has not been reported in GBM. This information could aid in design of combination strategies that potentiate apoptosis, identify biomarkers of drug efficacy, and help anticipate drug resistance 21 . Another important question concerning MRZ utility for GBM treatment involves drug delivery to brain tumors. The blood brain barrier (BBB) may prevent drug delivery to brain tumors, while BBB disruption by brain . Though a previous study indicated that MRZ did not decrease proteasome activity in the brain, this was in mice without brain tumors, and therefore with intact BBB 10, 23 . It is important to use orthotopic tumor models to answer these questions. This issue may explain the mixed results with BTZ in vivo. Despite strong in vitro efficacy 24, 25 , the combination of BTZ and the histone deacetylase inhibitor (HDACi) vorinostat failed to prevent progression in GBM patients in a phase II clinical trial 26 . This trial did not include molecular markers to indicate whether BTZ successfully inhibited proteasomes in brain tumors at the dose and treatment schedule used. This illustrates why proteasome inhibitors with unique properties, such as MRZ, should be carefully studied to define their in vivo dynamics.
Past in vitro and clinical experience with proteasome inhibitors has demonstrated important needs in two avenues of research: 1) determining events necessary for proteasome inhibitor efficacy that can serve as biomarkers and 2) testing next-generation proteasome inhibitors such as MRZ that may have unique delivery, inhibitory, and death-inducing properties leading to enhanced clinical efficacy. Therefore, the goals of this study were to establish the pathway of cell death induced by MRZ in GBM and to evaluate its ability to affect changes in proteasome substrates and death induction in combination with vorinostat in an orthotopic GBM model.
Results
Proteasome inhibition by pulse treatment with MRZ in vitro and in vivo. As an irreversible inhibitor of the proteasome, MRZ should be able to induce sustained proteasome inhibition after brief exposure. We examined proteasome inhibition and DNA fragmentation in LN18 GBM cells treated with short pulses of MRZ or the reversible inhibitor BTZ. Cells were treated with drug for the times indicated in the figure; after that time, wells were washed with PBS and fresh media was added until a total of 24 h had passed for measurement of proteasome activity (Fig. 1a) , or 48 h had elapsed for assessment of DNA fragmentation (Fig. 1b) . MRZ treatments as short as 2 h caused proteasome inhibition that was sustained out to 24 h. However, longer exposure to BTZ was necessary to achieve the same effects. Shorter MRZ treatments also induced DNA fragmentation, while BTZ required longer exposures.
To study this effect in vivo and to establish the inhibitory capacity of MRZ in an intracranial brain tumor model, mice with orthotopic U87 cell brain tumors that had developed for 1 week were treated with a single intraperitoneal injection of MRZ or BTZ. Doses of MRZ and BTZ (0.15 mg/kg and 1.0 mg/kg, respectively) were chosen based on established maximum tolerated doses 10, 27 . Twenty-four hours after treatment, we observed increased levels of the proteasome substrate p27 in lysates from the tumor-bearing portion of the brain of MRZ-treated mice (Fig. 1c,d ). Sustained proteasome inhibition yields increased death in GBM in vitro and in vivo. In addition to our examination of single pulse treatments (Fig. 1) , we also examined the action of MRZ and BTZ in a panel of GBM cell lines after continuous treatment. Both agents caused strong initial proteasome inhibition in GBM cells, though MRZ-treated cells recovered proteasome activity between 16 and 24 h, whereas BTZ caused more sustained inhibition (Fig. 2a) . Treatment with the vehicle (DMSO) did not significantly impact proteasome activity (Supp. Fig. 1 ). Blocking drug efflux with verapamil, an inhibitor of P-glycoprotein, did not enhance the activity of either drug, suggesting that efflux does not account for the recovery after MRZ treatment (Supp. Fig. 2 ). Viability measurement using trypan blue demonstrated that GBM cell lines were sensitive to both MRZ and BTZ at nanomolar doses (Fig. 2b) . LN18 cells treated with MRZ and BTZ also had increased DNA fragmentation (Fig. 2c ) and decreased colony growth (Fig. 2d) .
The increased death caused by BTZ in Fig. 2b-d suggests a link between more sustained proteasome inhibition ( Fig. 2a) and increased death. To examine this effect in vivo, mice with orthotopic U87 brain tumors that had developed for 2 weeks were treated for a more continuous period: twice weekly for 2 weeks (representative H&E stained control brain with tumor, Fig. 2e ). There was an increase in the number of p21-positive cells in tumors from MRZ-or BTZ-treated mice (Fig. 2f,g ). Therefore, both MRZ and BTZ affect proteasome substrates in vivo after multiple treatments.
Proteasome inhibitors induce caspase-dependent death in leukemia 8 . To assess whether this was also true in GBM, we examined initiator caspases 2, 8, and 9 after treatment with MRZ or BTZ. All 3 caspases were cleaved, a step in the activation process, after treatment with BTZ and MRZ (Fig. 3a) . Caspase 2 was cleaved after 4 h, particularly with MRZ, whereas caspases 8 and 9 were cleaved later (8-12 h). Executioner caspase 3/7 activity was detected 16 h after treatment (Fig. 3b) . Nearly all DNA fragmentation induced by BTZ and MRZ was blocked by pre-treatment with the pan-caspase inhibitor z-VAD-fmk, and viability was also increased (Supp. Fig. 3 ). This indicates that caspases play a crucial role in death induction by proteasome inhibitors in GBM cells (Fig. 3c ).
Early cleavage of caspase 2 by proteasome inhibitors is not essential for death. After observing early cleavage of caspase 2, we used a more direct method to confirm that this caspase 2 cleavage represented caspase 2 activation. We measured recruitment of caspase 2 to activation platforms, the initiating step in its activation, using a Venus bimolecular fluorescence (BiFC) model that measures induced proximity of caspase 2 ( Fig. 4a) . For this experiment, we used doses of MRZ and BTZ (290 nM and 15 nM, respectively) that were equipotent, meaning that they resulted in DNA fragmentation in 50% of the cells after 48 h (Fig. 2c) . Both MRZ and BTZ induced caspase 2 BiFC, with MRZ inducing caspase 2 activation slightly earlier than BTZ (Fig. 4b) .
To examine the importance of caspase 2 in proteasome inhibitor-induced death, we generated LN18 cells stably expressing caspase 2 shRNA (Fig. 4c) . Active caspase 2 has been shown to induce mitochondrial membrane permeability and activation of caspase 9 28, 29 . However, shCASP2 cells treated with MRZ or BTZ had increased cleavage of caspase 9 ( Fig. 4d ), increased caspase 3/7 activity (Fig. 4e) , and slightly increased overall DNA fragmentation ( Fig. 4f ). In addition to the stable knockdown of caspase 2, we also observed that transient knockdown with siRNA against caspase 2 did not impact induction of death following proteasome inhibition (Supp. Fig. 4 ). Therefore, caspase 2 does not appear to be essential for death induction following proteasome inhibition in GBM.
Caspase 9 functions upstream of caspase 8 to induce death after proteasome inhibition. We next examined the initiator caspases 8 and 9, which were activated 8-12 h following proteasome inhibition (Fig. 3a) . Pre-treatment with specific inhibitors of either caspase 8 (z-IETD-fmk) or caspase 9 (z-LEHD-fmk) significantly protected cells from both MRZ-and BTZ-induced DNA fragmentation (Fig. 5a ). To identify the initiator of the caspase cascade, we examined whether chemical inhibition of either caspase 8 or 9 blocked activation of the other caspase. These inhibitors act as caspase substrates; after initial cleavage of the targeted caspase, the inhibitors bind the active caspase to prevent cleavage of downstream substrates. Therefore, initial cleavage of the targeted caspase will (Fig. 5b-d) .
Caspases have overlapping cleavage site specificities, so chemical inhibitors are not specific for any one caspase 30 . Therefore, we confirmed our results in cells stably expressing shRNA for caspase 8 or 9. Twenty-four hours after proteasome inhibitor treatment, shCASP8 cells showed decreased sensitivity to MRZ, but not BTZ (Fig. 5e) . Notably, shCASP9 cells were more resistant to both MRZ and BTZ, indicating that caspase 9 is important for initial death induction by both inhibitors. These effects were blunted after 48 h of treatment, indicating that late compensatory mechanisms may obscure early death events (Fig. 5f) . However, the data at 24 h confirms that caspase 9 is important for initial death induction by both MRZ and BTZ.
Caspase activation was also examined in shCASP8 and shCASP9 cells treated with MRZ and BTZ (Fig. 5g) . Caspase 8 activation was blocked in shCASP9 cells (Fig. 5h) , while caspase 9 activation was not diminished in shCASP8 cells (Fig. 5i) , confirming the result with the chemical inhibitors. Together, data from both chemical inhibitors and shRNA indicates that caspase 9 is at the top of the apoptotic cascade induced by both MRZ and BTZ in GBM cells.
Caspase 9 activation and death are blocked by reducing agents. In other cancer types, production of reactive oxygen species (ROS) is an integral part of proteasome inhibitor-induced death 8, [31] [32] [33] . To study effects of ROS, we pre-treated cells with N-acetylcysteine (NAC), an antioxidant that increases cellular glutathione (GSH), or dithiothreitol (DTT), a general reducing agent. Pre-treatment with NAC or DTT diminished mitochondrial release of cytochrome C, cleavage of caspase 9 (Fig. 6a) , caspase 3/7 activity (Fig. 6b) , and DNA fragmentation (Fig. 6c ) in LN18 cells treated with BTZ and MRZ. Reductions in caspase activation were more pronounced in cells treated with reducing agents and MRZ compared to BTZ.
Since the antioxidant mechanism of NAC is widely considered to be through increased GSH, we also pre-treated cells with cell-soluble glutathione ethyl ester (GSHee). Though GSHee and NAC similarly raised GSH levels (Fig. 6d) , GSHee did not prevent proteasome inhibitor-induced DNA fragmentation (Fig. 6c) . Additionally, inhibition of GSH synthesis by buthionine sulphoximine (BSO) depleted GSH (Fig. 6d ) but did not prevent NAC from protecting cells from proteasome inhibitors (Fig. 6e) . Importantly, NAC and DTT did not attenuate the ability of BTZ and MRZ to reduce proteasome activity (Fig. 6f) . These results indicate that the reducing agents NAC and DTT may protect from proteasome inhibitor-induced death by preventing upstream apoptotic events through GSH-independent mechanisms, without affecting the proteasome inhibitory activity of BTZ and MRZ.
HDACi synergize with proteasome inhibitors in vitro and in vivo. Development of combination treatment regimens is essential for a viable clinical strategy. Previous studies in other cancer types have indicated that combining proteasome inhibitors with HDACi can be a potent therapeutic strategy 8, 34 . BTZ plus the HDACi vorinostat induced a strong reduction in mitochondrial membrane potential in GBM cells 25 , and we found that this combination amplifies caspase 9 cleavage (Fig. 7a) . We analyzed DNA fragmentation in cells treated with either BTZ or MRZ and two different HDACi: the FDA-approved inhibitor vorinostat (Fig. 7b) and a newer HDACi, panobinostat (Fig. 7c) . Using CalcuSyn software to analyze our DNA fragmentation results, we identified multiple synergistic combinations for BTZ and MRZ and both HDACi (Fig. 7d) .
We next examined this combination in vivo. Mice with intracranial tumors were treated by the schedule outlined in Fig. 7E , and tumors were examined for cleaved lamin A, a caspase substrate (Fig. 7f ). Mice treated with MRZ or BTZ plus vorinostat had significantly increased cleaved lamin A-positive cells compared to control mice (Fig. 7g) .
Discussion
This is the first study to evaluate functional effects of MRZ in an orthotopic GBM model. We demonstrated enhanced proteasome inhibition by MRZ after pulse treatments and single injection in vitro and in vivo, which could be beneficial for integrating this agent into a chemotherapy regimen. Though MRZ was less potent than BTZ after continuous treatment in vitro, our in vivo data suggests a different dynamic in an orthotopic model, perhaps due to better BBB penetration of MRZ. Future studies using radiolabeled MRZ in orthotopic models would be required to adequately answer this question.
This study also found that MRZ and BTZ induce caspase 9 initiated apoptosis in GBM cells. Events specifically related to this pathway may be useful in future clinical trials to aid interpretation of efficacy results and anticipate and overcome drug resistance. These results also indicate that MRZ acts differently in GBM cells compared to myeloma and leukemia, where it was shown to be dependent on caspase 8 8, 16 . Though we were able to show caspase 2 activation by 2 methods, we found that knockdown of caspase 2 did not impact death induction by proteasome inhibitors. Previous reports have described a role of caspase 2 as a tumor suppressor, and have found that cells deficient in caspase 2 show increased proliferation and defective cell cycle checkpoint regulation after DNA damage 35 . Therefore, caspase 2 activation may have interesting functions that warrant future investigation.
In addition to caspase 9 inhibition, treatment with NAC or DTT also blocked caspase activation and cell death in a manner independent of GSH. NAC and DTT may impact thiol levels to create a reduced cellular environment. Thiol modulation can impact cellular stress responses, as DTT and NAC have been shown to prevent heat shock death in endothelial cells, whereas GSH was not protective 36 . Given their broad effects on the cellular environment, NAC and DTT may affect many proteins in stress response and cell death pathways. Vitamin C and other antioxidants have been shown to prevent BTZ efficacy in myeloma 37 , and thiol-rich agents should also be evaluated for contraindications. Our study suggests that GSH, but not NAC, may be an appropriate treatment to alleviate side effects such as BTZ-associated peripheral neuropathy 38 . Combination strategies are key to clinical efficacy of these agents. MRZ and BTZ synergized with HDACi in vitro and induced cleavage of lamin A in vivo. There was a trend toward increased lamin A cleavage in mice treated with vorinostat plus MRZ versus the combination with BTZ, indicating once again that MRZ may be exerting a stronger effect than BTZ in vivo.
This study highlights the idea that new proteasome inhibitors and HDACi have improved targeting and clinical utility. Besides MRZ, this study also examined panobinostat, a novel HDACi that has shown promise in combination with BTZ in myeloma 39, 40 . In the current study, panobinostat synergized with both MRZ and BTZ at lower doses than vorinostat in vitro, indicating that this combination warrants future examination. Agents such as MRZ and panobinostat have promising preclinical properties, and they warrant careful examination to delineate their clinical potential. Future experiments in relevant models will also be able to assess the ability of MRZ to impact tumor size and survival as part of various therapeutic combinations.
Materials and Methods
Cell lines and reagents. All GBM cell lines (LN18, SNB19, U87, and U251) were obtained from ATCC. The cells used possess varied genetic characteristics: U87 cells are wild-type for p53, while SNB19, U251, and LN18 express mutant p53; LN18 cells express wild-type PTEN, while U87, SNB19, and U251 cells have altered PTEN status. Cells were authenticated by the Characterized Cell Line Core Facility at MD Anderson Cancer Center using the short tandem repeat method. Cells were maintained in an incubator at 37 °C with 5% CO 2 in DMEM/ F12 media with 10% FBS, 1% penicillin and streptomycin, and 1% L-glutamine. BTZ was obtained from LC Labs (Woburn, MA) and MRZ was provided by Nereus Pharmaceuticals (San Diego, CA).
Proteasome activity assay. Cells were washed 1× with PBS and resuspended in 20S proteasome lysis buffer (20 mM Tris, pH 7.5, 0.1 mM ethylenediaminetetraacetic acid, 20% glycerol, and 0.05% NP-40 supplemented each time with fresh 1 mM β -mercaptoethanol and 1 mM adenosine triphosphate). Cells were lysed by freezing and thawing 3× on dry ice. Samples were then spun for 1 min at 12,000 rpm. Samples were aliquoted to duplicate wells (100 μ L/well) of a black 96-well plate. Next, 98 μ L substrate buffer (50 mM HEPES, pH 7.5, and 50 mM EGTA, pH 7-8) were added to each well along with 2 μ L suc-LLVY-amc fluorogenic substrate for chymotrypsin-like activity (AG Scientific, San Diego, CA, USA). After 1 h incubation with fluorogenic substrates, fluorescence was read on a Gemini EM Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) at an excitation of 380 nM and an emission of 460 nM. For experiments that indicate they were standardized to DMSO, all samples were divided by the fluorescence value for control (DMSO treated) cells.
Cell viability and DNA fragmentation. Viability was measured by trypan blue exclusion assay using a Colony growth assay. Colonies were grown in soft agarose as described previously 41 . A base agarose layer was formed by mixing 10 mL sterile water containing 4% low-melt agarose with 85 mL DMEM/F12 media containing 10% FBS and 15 mL additional FBS. The base agarose (0.5 mL) was added to each well in a 24-well plate. Then, a top agarose layer was formed by mixing 10 mL sterile water containing 3% low-melt agarose with 42.5 mL DMEM/F12 media containing 10% FBS and 7.5 mL additional FBS. LN18 cells were added to the top agarose (1,300 cells/mL), and 0.5 mL top agarose containing cells was added to each well of the 24-well plate on top of the base layer of agarose. After the top matrix solidified, 300 μ L warm media was added to the top of each well. Cells were grown in these plates for 5 days. After 5 days, proteasome inhibitors were added to the top media of each well in doses normalized to the volume of the agar plus top media, and cells were incubated with the drug for 3 additional days. Wells were analyzed using a GelCount ™ machine (Oxford Optronix, Oxfordshire, England). Biomass was calculated as the number of colonies multiplied by the average volume.
Western blotting. Cells were lysed for 1 h at 4 °C in Triton X-100 lysis buffer (PBS containing 1% Triton X-100, 25 mM Tris, pH 7.5, and 157 mM NaCl) supplemented with a cOmplete Mini protease inhibitor cocktail tablet (Roche, Basel, Switzerland) and 1 mM glycerol phosphate, 1 mM NaF, and 1 mM NaOrthoV. Debris was pelleted by spinning samples for 20 min at 12,000 rpm at 4 °C, and protein concentrations were determined by Bradford Assay (Bio-Rad, Hercules, CA, USA).
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. After blocking for 1 h at room temperature in 5% milk or bovine serum albumin in TBS-T, membranes were incubated with 1:1,000 dilutions of the following primary antibodies: actin (Sigma, St. Louis, MO, USA), caspase 8, caspase 9, tubulin (Cell Signaling, Beverly, MA, USA), caspase 2 (EMD Millipore, Billerica, MA, USA), cytochrome C, and p27 Kip1 (BD, San Jose, CA, USA). Membranes were then washed 3× with TBS-T before being incubated with appropriate horseradish peroxidase conjugated secondary antibodies (mouse and rabbit: GE Healthcare, Buckinghamshire, England; rat: Cell Signaling, Beverly, MA, USA). Chemiluminescent visualization of bands was performed using a Kodak film developer (Rochester, NY, USA). Bimolecular fluorescence complementation (BiFC) measurement of caspase 2 activation. Measurement of induced proximity of caspase 2 using the caspase-2 BiFC was performed as previously described 42 . LN18 cells were plated in a 4-chamber dish containing coverslips (Nunc, Roskilde, Denmark) 24 h prior to transfection. Cells were transfected with caspase 2-CARD-VC (100 ng/well), caspase 2-CARD-VN (100 ng/well), and dsRed mito (20 ng/well) using lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA). The following day, cells were treated with 290 nM MRZ or 15 nM BTZ. Cells were imaged using a spinning disk confocal microscope (Zeiss, Jena, Germany) equipped with a CSU-X1A 5000 spinning disk unit (Yokogowa Electric Corporation, Japan), multi-laser module with wavelengths of 458 nM, 488 nM, and 514 nM, and an Axio Observer Z1 motorized inverted microscope equipped with a precision motorized XY stage (Carl Zeiss MicroImaging, Thornwood, NY, USA). Temperature was maintained at 37 °C and 5% CO 2 using an environmental control chamber. Zen 2012 software (Zeiss) was used to acquire images using a Zeiss Plan-Neofluar 40 × 1.3 NA objective on an Orca R2 CCD camera and to analyze average Venus intensity.
Specific chemical and shRNA inhibition of caspases 2, 8, and 9. Cells were pre-treated with specific inhibitors of caspase 8 (25 μ M z-IETD-fmk) or caspase 9 (25 μ M z-LEHD-fmk) (Enzo Life Sciences, Farmingdale, NY), followed by treatment with proteasome inhibitors as described.
To generate LN18 cells with stable knockdown of caspases, GIPZ lentiviral shRNA was obtained from GE Healthcare (Buckinghamshire, England) with sequences targeting caspase 2 (CAGACATCTCCTTGCACCG), caspase 8 (TTCTTAGTGTGAAAGTAGG), and caspase 9 (TGTCGTCAATCTGGAAGCT). Lentiviral infection of LN18 cells was performed using a Trans-Lentiviral Packaging Kit from Thermo Fisher Scientific (Waltham, MA) followed by puromycin selection.
Glutathione measurement. Cells were washed 1× in PBS and resuspended in 1 mL PBS. Next, 2 μ L monochlorobimane solution (2.2 mg monochlorobimane in 194.12 μ L acetonitrile) was added to each sample. Samples were vortexed and incubated at 37 °C for 15 min. The reaction was halted by adding 50 μ L trichloroacetic acid and vortexing. Samples were spun for 5 min at 10,000 rpm, and 1 mL supernatant was added to a glass tube containing 1 mL dichloromethane. Glass tubes were vortexed and centrifuged for 2 min at 3,500 rpm. For each sample, 200 μ L of the top aqueous layer was plated in duplicate wells in a white 96-well plate. Fluorescence was read on a Gemini EM Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) at an excitation of 360 nM and an emission of 460 nM. Glutathione concentrations were determined by comparing samples to a standard curve composed of varying concentrations of glutathione ethyl ester dissolved in PBS. Care. An intracranial guidescrew model of GBM was used, as previously described 43 . We implanted 500,000 U87 GBM cells though a guidescrew in 5-week-old female athymic nude mice (Experimental Radiation Oncology, MD Anderson, Houston, TX) and let tumors develop for 1-2 weeks (as noted in Results). Mice were then injected intraperitoneally with 1 mg/kg BTZ, 0.15 mg/kg MRZ, and/or 50 mg/kg vorinostat in dosing schedules outlined in the Results. For lysates, the tumor sections were frozen in liquid nitrogen, then homogenized by vortexing with zirconia/silica beads (Biospec, Bartlesville, OK, USA) in lysis buffer (20 mM Tris, pH 7.5, 0.1 mM EDTA, 20% glycerol, and 0.05% NP-40). For IHC analysis, samples were preserved in formalin, then paraffin-embedded.
Immunohistochemistry. Proteins 
Statistical analysis.
Values are given as the mean ± standard error of the mean, with all experiments performed at least in triplicate. Comparisons were made using Student's t-tests performed using GraphPad Prism software, version 6 (GraphPad software, La Jolla, CA). P-values < 0.05 were considered significant. Synergy was determined based on DNA fragmentation assays using CalcuSyn software (Biosoft, Cambridge, United Kingdom), with combination index (CI) values < 1 considered synergistic.
